Prescribed Medication for Acute Treatment for Migraine Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Type (Abortive and Prophylactic), By Route of Administration (Oral, Injectables and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) and Region Forecast 2019-2030

Prescribed Medication For Acute Treatment For Migraine Market size estimated to be valued at US$ 2,587.9 million in 2023 and is poised to grow at a significant CAGR of 13.7% over 2024-2030. The market for prescribed medications for acute treatment of migraine is expected to offer lucrative opportunities for the market players due to the launch of novel molecules in the U.S. market. The companies have focused on novel therapeutics, an alternative to the triptan class of drugs due to the adverse effects like cardiovascular disorders, chest pressure, and others. Novel treatment options and increased prevalence of migraine are expected to drive the market. Increased awareness initiatives, the availability of research funds from private and public bodies, a development in the reimbursement scenario for associated medications, and increasing awareness about the effectiveness of such medicines are among the significant factors fuelling the market's growth.

Furthermore, rising pharmaceutical R&D operating costs and rising healthcare spending are expected to drive the global prescribed medications for acute migraine treatment market growth rate during the forecast period. In the prescribed medications for acute treatment of migraine market, abortive prescribed medications for acute treatment of migraine accounted for a larger revenue share in 2021 and are projected to grow with a CAGR of 13.9% from 2022-2028 to reach US$ 1,653.7 Mn by 2028. However, the market for prophylactic drugs is anticipated to grow with a significant CAGR over the forecast years in prescribed medications for acute treatment of migraine.

Key Developments

• In February 2022, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. It is recommended as the 75 mg dose of Rimegepant (available as an orally dissolving tablet) for marketing authorization for both the acute treatment of migraine with or without aura in adults and the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.
• In January 2022, BioDelivery Sciences launched a new drug Elyxyb (celecoxib oral solution), a fast-acting liquid. It is one of the first Food and Drug Administration-approved ready-to-use oral solutions for adults in the acute treatment of migraine, with or without aura.